Riociguat Tablets are a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 1, 2022 | Original application | Approved |
| Aug 4, 2026 | Supplement 2REMS | Approved | None posted |
| May 8, 2026 | Supplement 1REMS | Approved | None posted |
| Sep 1, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters